New US label data for Novo Nordisk's Victoza
This article was originally published in Scrip
Executive Summary
The US FDA has approved changes to the labelling for Novo Nordisk's diabetes drug Victoza (liraglutide) to include data showing that it is more effective than rival product, Merck & Co's DPP-IV inhibitor Januvia (sitagliptin). The new labelling also adds data on Victoza's use in combination with basal insulin for the treatment of adults with type 2 diabetes.